Expression of cluster of differentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic significance

Chen,Zhanhong; Xu,Shenhua; Xu,Weizhen; Huang,Jian; Zhang,Gu; Lei,Lei; Shao,Xiying; Wang,Xiaojia

doi:10.3892/ol.2015.3348

August-2015 Volume 10 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2015 Volume 10 Issue 2

Full Size Image

Article Open Access

Expression of cluster of differentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic significance

Authors:
- Zhanhong Chen
- Shenhua Xu
- Weizhen Xu
- Jian Huang
- Gu Zhang
- Lei Lei
- Xiying Shao
- Xiaojia Wang
View Affiliations / Copyright

Affiliations: Key Laboratory of Technology Research on the Diagnosis and Treatment of Thoracic Cancer, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China

Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 723-729
|
Published online on: June 10, 2015

https://doi.org/10.3892/ol.2015.3348
Expand metrics +

Abstract

The aim of the present study was to investigate the immunohistochemical expression of cluster of differentiation (CD) 34 and vascular endothelial growth factor (VEGF) in breast cancer tissue, and their prognostic significance. High CD34 expression levels (microvessel density, >15/HPF) were identified in 27.3% (12/44) of cases, exhibiting no significant correlation with the clinicopathological characteristics of the patients. However, Kaplan‑Meier analysis demonstrated that the survival time of patients with high CD34 expression was significantly shorter than that of patients with low CD34 expression (50.0 vs. 90.6%; P=0.003). Samples with high VEGF expression levels (++ or +++) accounted for 63.6% (28/44) of the total number of cases. High VEGF expression was significantly prevalent in patients aged ≥50 years compared with patients aged <50 years (≤78.6 vs. 37.5%; P=0.006). Furthermore, all patients with vascular invasion exhibited high VEGF expression levels; thus, patients with vascular invasion presented with significantly higher VEGF expression rates compared with patients with no vascular invasion (100.0 vs. 55.6%; P=0.018). However, Kaplan‑Meier analysis demonstrated that high VEGF expression was not correlated with the overall survival of the patients (P=0.366). By contrast, Cox multivariate analysis identified that clinical stage, triple‑negative subtype and age were independent prognostic factors for patients with breast cancer (P=0.005, P=0.006 and P=0.032, respectively), and that CD34 expression was a potential independent prognostic factor (P=0.055). Therefore, the present study determined that for patients with breast cancer, a high level of CD34 expression may be a potential indicator of a poor prognosis.

View Figures

View References

1	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
2	Ziyad S and Iruela-Arispe ML: Molecular mechanisms of tumor angiogenesis. Genes Cancer. 2:1085–1096. 2011. View Article : Google Scholar : PubMed/NCBI
3	Cao Y, Zhang ZL, Zhou M, et al: Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer. 119:313–324. 2013. View Article : Google Scholar : PubMed/NCBI
4	Zorgetto VA, Silveira GG, Oliveira-Costa JP, Soave DF, Soares FA and Ribeiro-Silva A: The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A) expression with clinical-pathological features and survival in pancreatic adenocarcinomas. Diagn Pathol. 8:1702013. View Article : Google Scholar : PubMed/NCBI
5	Horn LC, Schreiter C, Canzler A, Leonhardt K, Einenkel J and Hentschel B: CD34(low) and SMA(high) represent stromal signature in uterine cervical cancer and are markers for peritumoral stromal remodeling. Ann Diagn Pathol. 17:531–535. 2013. View Article : Google Scholar : PubMed/NCBI
6	Zhan H, Liang H, Liu X, Deng J, Wang B and Hao X: Expression of Rac1, HIF-1α and VEGF in gastric carcinoma: correlation with angiogenesis and prognosis. Onkologie. 36:102–107. 2013. View Article : Google Scholar : PubMed/NCBI
7	Sundov Z, Tomic S, Alfirevic S, et al: Prognostic value of MVD, LVD and vascular invasion in lymph node-negative colon cancer. Hepatogastroenterology. 60:432–438. 2013.PubMed/NCBI
8	Dhakal HP, Nesland JM, Førsund M, Trope CG and Holm R: Primary tumor vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact. BMC Cancer. 13:5062013. View Article : Google Scholar : PubMed/NCBI
9	Anannamcharoen S and Nimmanon T: Study of the vascular endothelial growth factor (VEGF) expression and microvascular density (MVD) in primary colorectal cancer specimens. J Med Assoc Thai. 95:1041–1047. 2012.PubMed/NCBI
10	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: Breast CancerAJCC Cancer Staging Manual. 7th. Springer-Verlag; New York, NY: pp. 223–240. 2009
11	Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995. View Article : Google Scholar : PubMed/NCBI
12	Keyhani E, Muhammadnejad A, Behjati F, et al: Angiogenesis markers in breast cancer - potentially useful tools for priority setting of anti-angiogenic agents. Asian Pac J Cancer Prev. 14:7651–7656. 2013. View Article : Google Scholar : PubMed/NCBI
13	Satterthwaite AB, Burn TC, Le Beau MM and Tenen DG: Structure of the gene encoding CD34, a human hematopoietic stem cell antigen. Genomics. 12:788–794. 1992. View Article : Google Scholar : PubMed/NCBI
14	Ch'ng ES, Tuan Sharif SE and Jaafar H: Characteristics of invasive breast ductal carcinoma, NOS, diagnosed in a tertiary institution in the East Coast of Malaysia with a focus on tumor angiogenesis. Asian Pac J Cancer Prev. 13:4445–4452. 2012. View Article : Google Scholar : PubMed/NCBI
15	Murri AM, Hilmy M, Bell J, et al: The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer. 99:1013–1019. 2008. View Article : Google Scholar : PubMed/NCBI
16	Chuangsuwanich T, Pongpruttipan T, O-Charoenrat P, Komoltri C, Watcharahirun S and Sa-Nguanraksa D: Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand. Asian Pac J Cancer Prev. 15:1187–1192. 2014. View Article : Google Scholar : PubMed/NCBI
17	Staton CA, Hoh L, Baldwin A, Shaw L, Globe J, Cross SS, Reed MW and Brown NJ: Angiopoietins 1 and 2 and Tie-2 receptor expression in human ductal breast disease. Histopathology. 59:256–263. 2011.PubMed/NCBI
18	Davidson B, Stavnes HT, Førsund M, Berner A and Staff AC: CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival. Breast. 19:493–498. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zhao YC, Ni XJ, Li Y, Dai M, Yuan ZX, Zhu YY and Luo CY: Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients. World J Surg Oncol. 10:1652012. View Article : Google Scholar : PubMed/NCBI
20	Acs G, Paragh G, Rakosy Z, et al: The extent of retraction clefts correlates with lymphatic vessel density and VEGF-C expression and predicts nodal metastasis and poor prognosis in early-stage breast carcinoma. Mod Pathol. 25:163–177. 2012.PubMed/NCBI
21	Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
22	Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 28:3239–3247. 2010. View Article : Google Scholar : PubMed/NCBI
23	Robert NJ, Diéras V, Glaspy J, et al: RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 29:1252–1260. 2011. View Article : Google Scholar : PubMed/NCBI
24	Gonçalves A, Deblock M, Esterni B, et al: Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. Anticancer Drugs. 20:946–952. 2009. View Article : Google Scholar : PubMed/NCBI
25	Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V and Rugo HS: RIBBON-2: a randomized, double-blind, placebo- controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 29:4286–4293. 2011. View Article : Google Scholar : PubMed/NCBI
26	Theriault RL, Carlson RW, Allred C, et al: National Comprehensive Cancer Network: Breast cancer, version 3.2013: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 11:753–760. 2013.PubMed/NCBI
27	Huang H, Zheng Y, Zhu J, Zhang J, Chen H and Chen X: An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One. 9:e899602014. View Article : Google Scholar : PubMed/NCBI
28	Ni X, Zhao Y, Ma J, Xia T, Liu X, Ding Q, Zha X and Wang S: Hypoxia-induced factor-1 alpha upregulates vascular endothelial growth factor C to promote lymphangiogenesis and angiogenesis in breast cancer patients. J Biomed Res. 27:478–485. 2013. View Article : Google Scholar : PubMed/NCBI
29	Gao S, Ma JJ and Lu C: Prognostic significance of VEGF-C immunohistochemical expression in breast cancer: a meta-analysis. Tumour Biol. 35:1523–1529. 2014. View Article : Google Scholar : PubMed/NCBI
30	Srabovic N, Mujagic Z, Mujanovic-Mustedanagic J, Softic A, Muminovic Z, Rifatbegovic A and Begic L: Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor a. Int J Breast Cancer. 2013:7467492013. View Article : Google Scholar : PubMed/NCBI